Psychedelic drugs are making waves as modern trials support their therapeutic potential and various media continue to pique public interest. In this opinion piece, we draw attention to a long-recognised component of the psychedelic treatment model, namely ‘set’ and ‘setting’ – subsumed here under the umbrella term ‘context’. We highlight: (a) the pharmacological mechanisms of classic psychedelics (5-HT2A receptor agonism and associated plasticity) that we believe render their effects exceptionally sensitive to context, (b) a study design for testing assumptions regarding positive interactions between psychedelics and context, and (c) new findings from our group regarding contextual determinants of the quality of a psychedelic experience and how acute experience predicts subsequent long-term mental health outcomes. We hope that this article can: (a) inform on good practice in psychedelic research, (b) provide a roadmap for optimising treatment models, and (c) help tackle unhelpful stigma still surrounding these compounds, while developing an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
- Drug policy reform- the UNGASS 2016 a catalyst for change?
- Wastewater analysis and drugs: a European multi-city study 2018
- Vienna NGO Comitee on drugs annual report 2017
- The death penalty for drug offenders: global overview 2017
- Drug dependence treatment in Thailand: progress against persistent concerns
- The modernisation of treaty regimes: contrasting cases of international drug control and environmental regulation
- HIV and AIDS among adolescents who use drugs: opportunities for drug policy reform within the sustainable development agenda
- DPNSEE October-December newsletter
- What comes next? Post-UNGASS options for 2019 (Version 5)